Hints and tips:
...Shares of Anacor Pharmaceuticals, Sarepta Therapeutics, Exelixis and Prothena Corp have all climbed more than 100 per cent. Biotechs have also seen strong demand for new issuance....
...Oncothyreon Inc shares advanced 16 per cent to $3.96 after the Seattle-based company presented positive data on its experimental drug, ONT-380, in trials on breast cancer....
...Tuesday offered another lesson for investors in biotech: disappointing trial data can cut short a stock’s rally, as was the case with Exelixis....
...Mr Scangos, a former academic and executive at Bayer, was recruited to run Biogen Idec two years ago from Exelixis, a San Francisco-based drug company, after a period of troubles for the company which came...
...Under the agreement, relating to oncology, Sanofi would take on regulatory, production and commercial responsibilities and Exelixis would conduct clinical trials....
International Edition